Omeros finalizes with FDA clinical plan for OMS721 approval in IgA nephropathy
Omeros announced it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy following a recent meeting with the FDA. OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. January 17, 2019